AML: making residual disease more measurable

In this issue of Blood, Li et al(1) show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).

Automated summary

In this study, Li et al demonstrate that detection of leukemic stem cells (LSCs) using multiparameter flow cytometry (MFC) may be a better predictor of relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) compared to classical measurable residual disease (MRD).